P2RX4 and Stroke: Another experimental stroke study by the same group verified the detrimental role of P2X4 in brain ischemia by using the P2X4 antagonist 5-BDBD: When applied 4 hours (h) after tMCAO, 5-BDBD reduced infarct size, number of infiltrating pro-inflammatory myeloid cells, and blood-brain-barrier (BBB) disruption [24].